Palo Alto, CA, United States of America

Niv Papo

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2014-2016

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Niv Papo: Innovator in Cancer Treatment Technologies

Introduction

Niv Papo is a prominent inventor based in Palo Alto, CA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of polypeptides. With a total of 4 patents, Papo's work focuses on advancing medical technologies that target critical pathways in cancer progression.

Latest Patents

Niv Papo's latest patents include groundbreaking polypeptides that target vascular endothelial growth factor receptor-2 and αvβ3 integrin. These polypeptides comprise variant vascular endothelial growth factor sequences, which are instrumental in cancer imaging, diagnosis, monitoring, and treatment. Additionally, they are beneficial in addressing diseases characterized by excessive neovascularization, showcasing Papo's commitment to improving cancer care.

Career Highlights

Papo is affiliated with Leland Stanford Junior University, where he conducts his research and development. His work has garnered attention for its potential to revolutionize cancer treatment methodologies. His innovative approach and dedication to scientific advancement have positioned him as a key figure in the field.

Collaborations

Niv Papo collaborates with esteemed colleagues, including Jennifer R. Cochran and Adam Silverman. Their combined expertise enhances the research efforts and contributes to the development of effective cancer therapies.

Conclusion

Niv Papo's contributions to cancer treatment through his innovative polypeptides highlight his role as a leading inventor in the medical field. His work not only advances scientific knowledge but also holds promise for improving patient outcomes in cancer care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…